Payment overview · 2025
General Payments
$157.64
9 reported records · 6 companies
Healthcare provider profile · identity verified
Billy Glynn Branch, MD
Allopathic & Osteopathic Physicians|Internal Medicine · STERLINGTON, LA · NPI 1780975565
Verified facts
What the public records show
CMS Open Payments records show Billy Glynn Branch, MD received $157.64 in general payments during 2025 across 9 reported records.
Novo Nordisk Inc accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.08 | 31.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.59 | 23.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.45 | 12.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.58 | 11.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.88 | 10.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.06 | 10.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $157.64 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.08 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.08 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $36.59 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 114 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
114 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 473 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 412 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 411 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 408 | 122 |
| Gabapentin | Gabapentin | 370 | 109 |
| Omeprazole | Omeprazole | 361 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 303 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 279 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 278 | 90 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 274 | 63 |
| Lisinopril | Lisinopril | 252 | 56 |
| Tramadol Hcl | Tramadol Hcl | 243 | 57 |
| Montelukast Sodium | Montelukast Sodium | 234 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 226 | 64 |
| Clonazepam | Clonazepam | 209 | 32 |
| Famotidine | Famotidine | 185 | 54 |
| Alprazolam | Alprazolam | 184 | 26 |
| Furosemide | Furosemide | 183 | 66 |
| Eliquis | Apixaban | 181 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 52 |
| Prednisone | Prednisone | 171 | 123 |
| Zolpidem Tartrate | Zolpidem Tartrate | 170 | 25 |
| Trazodone Hcl | Trazodone Hcl | 169 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 168 | 47 |
| Potassium Chloride | Potassium Chloride | 165 | 47 |
| Pregabalin | Pregabalin | 165 | 35 |
| Baclofen | Baclofen | 156 | 65 |
| Metformin Hcl | Metformin Hcl | 155 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 151 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 44 |
| Glipizide Er | Glipizide | 149 | 45 |
| Lorazepam | Lorazepam | 146 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 137 | 39 |
| Meloxicam | Meloxicam | 137 | 54 |
| Simvastatin | Simvastatin | 136 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 134 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 37 |
| Celecoxib | Celecoxib | 130 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 127 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 118 | 30 |
| Donepezil Hcl | Donepezil Hcl | 117 | 32 |
| Mounjaro | Tirzepatide | 115 | 17 |
| Ozempic | Semaglutide | 114 | 24 |
| Finasteride | Finasteride | 109 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 105 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 103 | 25 |
| Bupropion Xl | Bupropion Hcl | 100 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 96 | 37 |
| Buspirone Hcl | Buspirone Hcl | 95 | 24 |
| Allopurinol | Allopurinol | 94 | 29 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 89 | 73 |
| Primidone | Primidone | 89 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 88 | 21 |
| Bumetanide | Bumetanide | 86 | 29 |
| Metformin Hcl Er | Metformin Hcl | 86 | 31 |
| Carvedilol | Carvedilol | 83 | 27 |
| Memantine Hcl | Memantine Hcl | 82 | 21 |
| Mirtazapine | Mirtazapine | 80 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 27 |
| Estradiol | Estradiol | 77 | 23 |
| Sertraline Hcl | Sertraline Hcl | 75 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 28 |
| Ezetimibe | Ezetimibe | 72 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 28 |
| Jardiance | Empagliflozin | 71 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 20 |
| Chlorthalidone | Chlorthalidone | 70 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 20 |
| Aripiprazole | Aripiprazole | 67 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 24 |
| Temazepam | Temazepam | 66 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | 17 |
| Warfarin Sodium | Warfarin Sodium | 64 | 12 |
| Methocarbamol | Methocarbamol | 63 | 16 |
| Carbamazepine Er | Carbamazepine | 62 | 12 |
| Glipizide | Glipizide | 61 | 20 |
| Ondansetron Odt | Ondansetron | 61 | 29 |
| Januvia | Sitagliptin Phosphate | 60 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 59 | 15 |
| Clonidine Hcl | Clonidine Hcl | 58 | 18 |
| Farxiga | Dapagliflozin Propanediol | 58 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 58 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 20 |
| Nifedipine Er | Nifedipine | 57 | 13 |
| Glimepiride | Glimepiride | 55 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 48 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 12 |
| Diazepam | Diazepam | 50 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 49 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | 14 |
| Lactulose | Lactulose | 49 | 23 |
| Fluconazole | Fluconazole | 48 | 36 |
| Valacyclovir | Valacyclovir Hcl | 47 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 46 | 24 |
| Colestipol Hcl | Colestipol Hcl | 45 | 14 |
| Fenofibrate | Fenofibrate | 45 | 14 |
| Mupirocin | Mupirocin | 45 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 37 |
| Rybelsus | Semaglutide | 39 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | 12 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 35 | 24 |
| Cefuroxime | Cefuroxime Axetil | 35 | 30 |
| Levofloxacin | Levofloxacin | 35 | 30 |
| Topiramate | Topiramate | 35 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | 12 |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Valsartan | Valsartan | 30 | 11 |
| Spironolactone | Spironolactone | 29 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 18 |
| Rizatriptan | Rizatriptan Benzoate | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | 15 |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Metolazone | Metolazone | 24 | 15 |
| Sucralfate | Sucralfate | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 21 |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 17 |
| Terbinafine Hcl | Terbinafine Hcl | 19 | 13 |
| Chlorzoxazone | Chlorzoxazone | 18 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 13 |
| Cephalexin | Cephalexin | 16 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Leflunomide | Leflunomide | 16 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Ramipril | Ramipril | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $157.64 · 9 records | Novo Nordisk Inc | CAPLYTA, NEXLETOL, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, WaveWriter Alpha Prime 16 | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error